Ritonavir Mylan 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0020/G 
This was an application for a group of variations. 
09/01/2024 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0019 
B.I.b.2.e - Change in test procedure for AS or 
28/08/2023 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0018 
C.I.z - Changes (Safety/Efficacy) of Human and 
17/05/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IAIN/0017 
B.II.b.1.a - Replacement or addition of a 
31/01/2023 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0016 
B.III.1.a.2 - Submission of a new/updated or 
06/12/2022 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
R/0015 
Renewal of the marketing authorisation. 
23/06/2022 
22/08/2022 
SmPC, 
Based on the review of data on quality, safety and efficacy, 
Labelling and 
the CHMP considered that the benefit-risk balance of 
PL 
Ritonavir Mylan in the approved indication remains 
favourable and therefore recommended the renewal of the 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0014/G 
This was an application for a group of variations. 
05/05/2022 
22/08/2022 
SmPC, 
marketing authorisation with unlimited validity. 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
T/0013 
Transfer of Marketing Authorisation 
24/09/2021 
18/11/2021 
SmPC, 
Labelling and 
PL 
IB/0012/G 
This was an application for a group of variations. 
08/09/2021 
18/11/2021 
SmPC, 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Labelling and 
PL 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0011 
A.7 - Administrative change - Deletion of 
16/02/2021 
18/11/2021 
Annex II and 
manufacturing sites 
PL 
IA/0010 
A.7 - Administrative change - Deletion of 
07/01/2021 
n/a 
manufacturing sites 
II/0007/G 
This was an application for a group of variations. 
06/11/2020 
21/04/2021 
SmPC and PL 
The SmPC sections 3, 6.3 and 6.5 have been updated as 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
B.II.b.3.b - Change in the manufacturing process of 
the finished or intermediate product - Substantial 
changes to a manufacturing process that may have a 
significant impact on the quality, safety and efficacy 
of the medicinal product 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
follows:  
3. 
PHARMACEUTICAL FORM 
Film coated tablet (tablet). 
Yellow, capsule shaped, biconvex, beveled edge film coated 
tablet, approximately 19.1 mm x 10.2 mm, debossed with 
‘M163’ on one side and plain blank on the other side. 
6.3 
Shelf-life 
18 months. 
After first opening, use within 45 days. 
6.5 
Nature and contents of container 
HDPE bottle with polypropylene screw cap with aluminium 
induction sealing liner wad and a desiccant. 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Labelling and Package Leaflet have been updated 
accordingly. 
compared to the originally approved batch size 
B.II.d.1.e - Change in the specification parameters 
and/or limits of the finished product - Change 
outside the approved specifications limits range 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.e.1.b.1 - Change in immediate packaging of the 
finished product - Change in type/addition of a new 
container - Solid, semi-solid and non-sterile liquid 
pharmaceutical forms 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
25/03/2020 
21/04/2021 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0008 
B.II.b.2.c.1 - Change to importer, batch release 
26/02/2020 
21/04/2021 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0006/G 
This was an application for a group of variations. 
15/10/2019 
14/11/2019 
SmPC, Annex 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
II, Labelling 
and PL 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0005/G 
This was an application for a group of variations. 
12/06/2019 
n/a 
B.II.b.5.c - Change to in-process tests or limits 
applied during the manufacture of the finished 
product - Deletion of a non-significant in-process test 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
Page 6/7 
 
 
 
 
 
 
 
 
 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
N/0004 
Minor change in labelling or package leaflet not 
15/03/2019 
06/05/2019 
PL 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0003 
C.I.z - Changes (Safety/Efficacy) of Human and 
27/11/2018 
06/05/2019 
SmPC 
Veterinary Medicinal Products - Other variation 
IB/0002 
C.I.z - Changes (Safety/Efficacy) of Human and 
09/07/2018 
06/05/2019 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
IAIN/0001 
B.II.e.5.a.1 - Change in pack size of the finished 
03/05/2018 
06/05/2019 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
PL 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
